CD19-targeting T cells for B cell cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of immune cell therapy (4SCAR19U T cells) designed to attack B-cell cancers. It may be an option if your cancer has the CD19 protein and you haven't had a prior CAR-T treatment that failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 6 months.
- Your cancer cells have a marker called CD19 on their surface.
- You are generally healthy enough to do daily activities (KPS score over 80).
- Your hemoglobin level is above 80 g/L.
- You can safely have blood cells collected for therapy.
- You do not have a serious infection, HIV, or active hepatitis B or C.
- You are not pregnant or breastfeeding.
- You have not taken steroids in the last week.
- You have not had a CAR-T treatment that failed before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a special cell therapy that targets two markers on cancer cells to treat certain blood cancers. It may help people whose cancer has not gotten better with other treatments.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins (CD19 and CD70) on your cancer cells. It is for patients with B-cell cancers that didn't respond to previous treatments.
This trial tests a personalized cell therapy that uses your own immune cells, modified to better find and attack lymphoma cells. It may help when standard treatments have not worked.
This trial tests a new type of CAR-T therapy (a treatment that trains your immune cells to attack cancer) for people with certain types of B-cell leukemia that are CD19 negative or have relapsed after CD19 treatment. It may help if your cancer has other markers like CD22 or CD123.
This trial tests a type of immune therapy called CAR-T cells to treat autoimmune diseases. The treatment targets B cells, which are part of the immune system that can attack your own body in autoimmune conditions.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.